In this issue of the European Journal of Preventive Cardiology, Colombo and colleagues explore the interesting association between serum potassium levels and mortality in patients with an acute coronary syndrome (ACS). 1 Through a sapient use of meta-analysis, the authors provide very interesting, and partially unexpected, results. The striking message they deliver is that the target potassium levels are narrower than expected, as only serum concentrations between 4.0 and 4.5 mEq/l were not associated with an increased risk of both short and long-term mortality after ACS. The narrow gap highlighted by the authors has profound clinical implications. As stated by the authors, the present meta-analysis challenges the current European Society of Cardiology guidelines, 2,3 that give no specific recommendations but consider as 'normal' a more traditional range between 3.5 and 5.0 mEq/l. According to the present meta-analysis, a serum level between 4.5 and 5.0 mEq/l, therefore well within the 'normal' recommended level, translates into an increased short and long-term risk of death (odds ratio (OR) 1.53 and 1.60, respectively), which further doubles when potassium levels are over 5.0 mEq/l. Moreover, the U-shaped relationship between serum concentration and mortality means that potassium could have a spot as a simple, reliable and low-cost risk marker in ACS, and could probably be implemented into the commonly used criteria for mortality in ACS, if its independency as a risk factor is confirmed.
Nonetheless, the paper by Colombo et al. leaves many unanswered questions.
First, while patients with hypokalemia have an increased risk of ventricular arrhythmias, the same was not reported for high potassium levels, which were, on the other hand, protective. It is well known that the high sympathetic activity during ACS stimulates the Na þ /K þ ATPase to pump potassium inside the cell. The intracellular influx increases the resting potential, facilitating the automatic activity of the non-ischaemic myocardium and the triggering of one 4 or even many ventricular events. 5 On the other hand, the mechanism underlying the increased mortality risk in hyperkalemic patients is still a matter of debate, and no hypotheses can be extrapolated from the present meta-analysis. In fact, while hyperkalemia leads to reduced cardiac excitability and, therefore, to atrioventricular block, sinus arrest and pulseless electrical activity, these are usually reported for potassium levels that are higher than 5.0 mEq/l, or even more. 4 Mildly increased potassium levels may also indicate renal failure, which constitutes a major risk factor for short-term and long-term survival in ACS. Until more data are available, it is feasible to hypothesise that a mildly increased potassium concentration (4.5-5.0 mEq/l) could be a marker of disease rather than a mortality cause by itself, while higher potassium levels directly expose the ACS patient to an increased risk of asystole and pulseless electrical activity.
Second, in everyday clinical practice, serum potassium levels differ widely according to the method used. In particular, it has been reported that the blood gas analyser, so commonly used for a quick assessment of electrolyte balance in many emergency departments, significantly underestimates potassium levels by as much as 0.6 mEq/l when compared to biochemistry essays. 6 Given the narrow 'safety margin' highlighted by Colombo and colleagues, 1 the advantage of a prompt availability of serum potassium concentration during the first steps of patient assessment could be overcome by the lack of accuracy, which, at least in ACS, seems to make quite a difference.
Another point to consider is how the variations in serum levels during the whole hospitalisation affect the outcome. Potassium homeostasis is mainly regulated by the Na þ /K þ ATPase and could be modified by a plethora of different factors (for the most important determinants of potassium balance in ACS, please see Figure 1 ). Moreover, the vast majority of the drugs prescribed in these patients impact on the serum potassium level, either through the glomerulus, the reninangiotensin-aldosterone system, or the sympathetic system. 7 The potassium range, defined as the difference between the minimum and maximum values during hospitalisation, has already been independently associated with mortality. 8 Therefore, we should not only focus on admission levels, but we should ensure that each patient will be in the optimal potassium range for as long as possible. This is true for the whole hospitalisation and even after discharge, until medical therapy has been fully uptitrated.
In conclusion, the paper by Colombo and colleagues opens up many important questions, which should be a good topic for future research. It also reminds us that, as is often the case, the virtue lies in the middle.
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